Get access

Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients

Authors


*Corresponding author, Department of Dermatology, University of Münster, Von-Esmarch-Str. 58, D-48149 Münster/Germany, tel. +49 251 835 6504; fax +49 251 835 6522; E-mail: luger@uni-muenster.de

Abstract

Background and objective  Pimecrolimus cream 1% is an effective treatment for atopic eczema. The aim was to investigate its efficacy in asteatotic eczema, a skin disease similar to atopic eczema and its associated dry skin and itching.

Methods  Single-centre, randomized, double-blind, vehicle controlled study in 40 patients with asteatotic eczema. Efficacy was assessed by eczema area and severity index (EASI), investigators global assessment (IGA), patient's self-assessment, and pruritus severity.

Results  After 4 weeks of treatment, EASI, the primary efficacy variable, was reduced by 62 ± 7% from baseline in patients on pimecrolimus, compared to 21 ± 14% in patients on vehicle (P = 0.013). With pimecrolimus there was also a better control of pruritus (P = 0.042) at week 4 whereas a better control of disease according to self-assessment could only be observed at weeks 2 (P = 0.01) and week 3 (P = 0.08).

Conclusion  Pimecrolimus cream 1% is effective in patients with asteatotic eczema.

Ancillary